m6A-ATP,100mM Sodium Solution |
| Catalog No.GB20006 |
m6A-ATP is a base-modified analog of ATP and an adenosine agonist with an ED50 value of 17.250 µM.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
m6A-ATP is an adenosine agonist with an ED50 value of 17.250 µM, and is a modulator of adenylate cyclase[1]. m6A-ATP inhibits hemoglobin accumulation and terminal maturation initiation in a concentration-dependent manner. In MEL cells, m6A-ATP reduces the mRNA of β-globin accumulated in the cytoplasm, affecting the structural integrity of this mRNA[2]. m6A-ATP slows down the growth rate of MEL cells, but basically does not inhibit cellular DNA synthesis and reduce cell viability and clonal potential[2]. Adenine, L-homocysteine, and/or L-methionine are all involved in the activated methylation cycle, enhancing m6A-ATP induced inhibition of initiation[3].
M6A modification is the most prevalent, abundant and conserved internal co-transcriptional modification in eukaryotic RNA, especially in higher eukaryotic cells[4]. M6A modification is considered as one of the post-transcriptional regulatory marks of different types of RNAs, including messenger RNAs (mRNAs), transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), circular RNAs (circRNAs), microRNAs (miRNAs) and long Noncoding RNAs (IncRNAs)[4]. M6A modification preferentially occurs within the consensus sequence RRACH (R = G or A; H = A, C or U) in the 3' UTRs and gene coding regions, and is involved in the processing and stability regulation of mRNA[5].
References:
[1]. Ribeiro JA and Sebastio AM. On the type of receptor involved in the inhibitory action of adenosine at the neuromuscular junction. Br J Pharmacol, 1985, 84(4):911-8.
[2]. Sinn P L and Sigmund CD. Human renin mRNA stability is increased in response to cAMP in Calu-6 cells. Hypertension, 1999, 33(3): 900-905.
[3]. Vizirianakis IS, Wong W and Tsiftsoglou AS. Analysis of the inhibition of commitment of murine erythroleukemia (MEL) cells to terminal maturation by N 6-methyladenosine. Biochemical pharmacology, 1992, 44(5): 927-936.
[4]. Shanshan Wang, et al. Dynamic regulation and functions of mRNA m6A modification. Cancer Cell International volume 22, Article number: 48 (2022)..
[5]. Zhao X, Yang Y, Sun BF, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell research, 2014, 24(12): 1403-1419.
| purity | >99.50% | Extinction Coefficient | |
| Formula | C11H18N5O13P3(freeacid) | M.Wt | 521.20(freeacid) |
| Salt Form | Concentration | ||
| Buffer | Storage | Store at -20°C | |
| Sinónimos | Backbone | ||
| Base Analog | Sugar Type | ||
| Nucleotide Category |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *